Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDRESBL-EC infections. Methods: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. Results: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBLEC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. Conclusions: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread.
Abstract
Background/Aims: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDRESBL-EC infections. Methods: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. Results: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBLEC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. Conclusions: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread.
참고문헌 (38)
- 정행순, "Prevalence of Plasmid-mediated Quinolone Resistance and Its Association with Extended-spectrum Beta-lactamase and AmpC Beta-lactamase in Enterobacteriaceae", Annals of Laboratory Medicine, 31(4), pp.257~264 (2011), 대한진단검사의학회
- Paterson DL, "International prospective study of Klebsiella pneumoniae bacteremia:implications of extended-spectrum beta-lactamase production in nosocomial Infections", Ann Intern Med, 140, pp.26~32 (2004)
- Pitout JD, "Extended-spectrum betalactamase-producing Enterobacteriaceae: an emerging public-health concern", Lancet Infect Dis, 8, pp.159~166 (2008)
- Paterson DL, "Extended-spectrum beta-lactamases:a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
- Rodriguez-Bano J, "Community-onset bacteremia due to extended-spectrum beta-lactamaseproducing Escherichia coli: risk factors and prognosis", Clin Infect Dis, 50, pp.40~48 (2010)
- Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
- Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
- 대한감염학회, "소화기계 감염 진료지침 권고안", Infection and Chemotherapy, 42(6), pp.323~361 (2010), 대한감염학회
- Kang CI, "Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli", Int J Antimicrob Agents, 36, pp.284~287 (2010)
- Hyle EP, "Risk factors for increasing multidrug resistance among extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella species", Clin Infect Dis, 40, pp.1317~1324 (2005)
- Kritsotakis EI, "Antibiotic use and the risk of carbapenemresistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients:results of a double case-control study", J Antimicrob Chemother, 66, pp.1383~1391 (2011)
- Park SY, "Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae", Microb Drug Resist, 18, pp.518~524 (2012)
- Serefhanoglu K, "Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance", Braz J Infect Dis, 13, pp.403~407 (2009)
- Rafailidis PI, "Case-control studies reporting on risk factors for emergence of antimicrobial resistance: bias associated with the selection of the control group", Microb Drug Resist, 16, pp.303~308 (2010)
- Kang CI, "Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains", J Clin Microbiol, 50, pp.312~317 (2012)
- Perl TM, "Long-term sur-vival and function after suspected gram-negative sepsis", JAMA, 274, pp.338~345 (1995)
- Friedman ND, "Health care: associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Garner JS, "CDC definitions for nosocomial infections, 1988", Am J Infect Control, 16, pp.128~140 (1988)
- Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP", SCCM Consensus Conference Committee. American College of Chest Physicians, Chest, pp.1992, 101[DOI]
- Kim J, "Occurrence of CTXM-3, CTX-M-15, CTX-M-14, and CTX-M-9 extendedspectrum beta-lactamases in Enterobacteriaceae clinical isolates in Korea", Antimicrob Agents Chemother, 49, pp.1572~1575 (2005)
- Kim J, "CTX-M and SHV-12 betalactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea", FEMS Microbiol Lett, 245, pp.93~98 (2005)
- Chung DR, "Evidence for clonal dissemination of the serotype K1 Klebsiella pneumoniae strain causing invasive liver abscesses in Korea", J Clin Microbiol, 46, pp.4061~4063 (2008)
- Tenover FC, "Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing", J Clin Microbiol, 33, pp.2233~2239 (1995)
- Apisarnthanarak A, "Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study", Am J Infect Control, 35, pp.606~612 (2007)
- Hsieh CJ, "Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL)and non-ESBL producing Escherichia coli", J Microbiol Immunol Infect, 43, pp.240~248 (2010)
- Lopez-Dupla M, "Previous ciprofloxacin exposure is associated with resistance to betalactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates", Am J Infect Control, 37, pp.753~758 (2009)
- Villers D, "Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology", Ann Intern Med, 129, pp.182~189 (1998)
- Giufre M, "Escherichia coli of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy", J Antimicrob Chemother, 67, pp.860~867 (2012)
- Kopterides P, "Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates", Int J Antimicrob Agents, 30, pp.409~414 (2007)
- Livermore DM., "Of pseudomonas, porins, pumps and carbapenems", J Antimicrob Chemother, 47, pp.247~250 (2001)
- Pascual FE, "Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation", Chest, 117, pp.503~512 (2000)
- Cho SY, "Clinical features and treatment outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli sequence type 131", Microb Drug Resist, 21, pp.463~469 (2015)
- Cha MK, "Comparison of the microbiological characteristics and virulence factors of ST131 and non-ST131 clones among extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia", Diagn Microbiol Infect Dis, 84, pp.102~104 (2016)
- Park SH, "The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli", J Antimicrob Chemother, 69, pp.2848~2856 (2014)
- Rodriguez-Bano J, "Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa", Grupo de Estudio de Infeccion Hospitalaria Group. Beta-lactam, Clin Infect Dis, pp.2012, 54[DOI]
- Ben-Ami R, "Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital", Clin Infect Dis, 42, pp.925~934 (2006)
- Harris AD, "Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli", Clin Infect Dis, 34, pp.1558~1563 (2002)
- Rodriguez-Bano J, "Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli", Arch Intern Med, 168, pp.1897~1902 (2008)